CS
CSTL icon

Candriam SCA’s Castle Biosciences CSTL Stock Holding History

Candriam SCA’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-22,812
Closed -$477K – 762
2023
Q1 		$477K Sell
22,812
-14,783
-39% -$361K ﹤0.01% 777
2022
Q4 		$885K Buy
37,595
+3,172
+9% +$73.5K 0.01% 721
2022
Q3 		$898K Buy
+34,423
New +$965K 0.01% 730

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Candriam SCA's CSTL Position: Q2 2023 in Review

Candriam SCA sold out of Castle Biosciences (CSTL) in Q2 2023, closing a stake of 22,812 shares — an estimated $477K sold.

Candriam SCA first reported a position in CSTL in Q3 2022 and held it in 3 quarters. The position peaked at $898K in Q3 2022. 130 funds tracked by Wall St. Rank hold CSTL as of Q2 2023.

  • Candriam SCA reported no remaining Castle Biosciences position as of Q2 2023 after selling out during the quarter.
  • Candriam SCA sold 22,812 Castle Biosciences shares in Q2 2023, an estimated $477K.
  • Candriam SCA first reported a position in Castle Biosciences in Q3 2022 and held it in 3 quarters.
  • Candriam SCA's Castle Biosciences position peaked at $898K in Q3 2022.
  • 130 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2023.

Based on Candriam SCA's 13F filing for Q2 2023, filed 8 Aug 2023.